Eli Lilly (LLY) Stock: Pharma Giant Eyes €15 Billion French Buyout

TLDR Eli Lilly preparing €15 billion acquisition offer for French biotech Abivax, awaiting French Finance Ministry guidance Tirzepatide generated $24.8 billion revenue in first nine months of 2025, becoming world’s best-selling drug Orforglipron oral weight loss treatment under priority review with decision expected by February 2026 Retatrutide achieved 28.7% mean weight loss in phase 3 [...]

The post Eli Lilly (LLY) Stock: Pharma Giant Eyes €15 Billion French Buyout appeared first on Blockonomi.